<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2160">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01797302</url>
  </required_header>
  <id_info>
    <org_study_id>PRO12100034</org_study_id>
    <secondary_id>R01HL112985</secondary_id>
    <secondary_id>5R01HL112985-05</secondary_id>
    <nct_id>NCT01797302</nct_id>
  </id_info>
  <brief_title>Vitamin D and Vascular Health in Children</brief_title>
  <official_title>Vitamin D and Vascular Function in Obese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will test the central hypothesis that enhancement of vitamin D status in&#xD;
      obese and overweight children will improve their vascular health and their cardiovascular&#xD;
      disease (CVD) and metabolic syndrome risk profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary objective is to determine, in obese and overweight children aged 10 to 18 years&#xD;
      with vitamin D deficiency (defined as serum 25-hydroxyvitamin D &lt;20 ng/mL), the efficacy of&#xD;
      enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial&#xD;
      stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether&#xD;
      these effects are dose-dependent. As a secondary objective, we will examine the vitamin D&#xD;
      supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk.&#xD;
      In a double-masked, controlled trial, we will randomize 252 eligible children to receive&#xD;
      either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced&#xD;
      supplementation) of vitamin D3 daily for 6 months.&#xD;
&#xD;
      In terms of reporting of results, the following pre-specified outcomes are included in the&#xD;
      primary manuscript (PubMed PMID:31950134 -- see Reference section for citation details)&#xD;
&#xD;
        1. Waist Circumference&#xD;
&#xD;
        2. Serum High Density Lipoprotein (HDL) Cholesterol&#xD;
&#xD;
        3. Serum Triglycerides&#xD;
&#xD;
        4. Inflammatory markers (Plasma TNF-alpha, high-sensitivity C-reactive protein, and IL-6)&#xD;
&#xD;
        5. Adiopkines (Plasma Leptin and Adiponectin)&#xD;
&#xD;
      Plasma nitric oxide metabolites were not measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">August 13, 2018</completion_date>
  <primary_completion_date type="Actual">August 13, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated Dilation (FMD) Percentage</measure>
    <time_frame>6 months</time_frame>
    <description>Brachial artery flow-mediated dilation percentage is a measure of endothelial function. FMD percentage calculation is based on baseline brachial artery diameter(brachialADbase) and change in brachial artery diameter (brachialADchange) during post-occlusive reactive hyperemia. FMD% was determined using the formula (brachialADchange/brachialADbase) x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse-wave Velocity (PWV)</measure>
    <time_frame>6 months</time_frame>
    <description>PWV is a measure of arterial stiffness. Higher values of PWV indicate greater degree of arterial stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index at Heart Rate of 75 Beats/Min (AIx-75)</measure>
    <time_frame>6 months</time_frame>
    <description>AIx-75 is a measure of arterial stiffness. AIx was measured through radial arterial tonometry using SphygmoCor.&#xD;
Radial pulse waveform are analyzed through an automatic software function to determine aortic pulse waveform and aortic or central systolic (cSBP) and diastolic blood pressure (cDBP), and these measurements are further analyzed automatically to calculate AIx.&#xD;
AIx is a composite measure of the magnitude of wave reflection and arterial stiffness in all conduit arteries which affect the timing of the wave reflection. AIx = P2-P1/cSBP-cDBP, where P1 is the height of the incident pressure wave form during systole, P2 is the height of the reflected wave added to the incident wave, cSBP is the aortic systolic BP, and cDBP is the aortic diastolic BP. AIx adjusted to heart rate of 75 beats/min (AIx-75) is a validated index of arterial stiffness, with higher values indicating higher degree of arterial stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>a measure of cardiometabolic health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Diastolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>a measure of cardiometabolic health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Systolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>a measure of cardiometabolic health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Diastolic Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>a measure of cardiometabolic health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>a measure of cardiometabolic health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1/Fasting Insulin Ratio</measure>
    <time_frame>6 months</time_frame>
    <description>1/fasting insulin ratio is a measure of insulin sensitivity. Increases in 1/fasting insulin ratio indicate improvements in insulin sensitivity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>6 months</time_frame>
    <description>a surrogate measure of adiposity</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Obesity</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 2000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 1000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Tablet form</description>
    <arm_group_label>Vitamin D3 1000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 2000 IU</arm_group_label>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible subjects will be 10 to 18 years of age;&#xD;
&#xD;
          -  obese or overweight (BMI ≥85th %tile);&#xD;
&#xD;
          -  otherwise healthy, and&#xD;
&#xD;
          -  have a serum 25(OH)D concentration &lt;20 ng/mL&#xD;
&#xD;
        Children taking multivitamins should be able to hold off their multivitamins during the&#xD;
        course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Children will be excluded if they&#xD;
&#xD;
          -  (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders, primary&#xD;
             hyperparathyroidism, hyperthyroidism, or other chronic disorders that could affect&#xD;
             vitamin D metabolism;&#xD;
&#xD;
          -  (b) are receiving treatment with anticonvulsants, systemic glucocorticoids,&#xD;
             pharmacologic doses of vitamin D (≥1000 IU of vitamin D2 or D3 daily),&#xD;
             antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or&#xD;
             other oral insulin regulators;&#xD;
&#xD;
          -  (c) have cholelithiasis or urolithiasis;&#xD;
&#xD;
          -  (d) have type 1 or type 2 diabetes; or&#xD;
&#xD;
          -  (e) have a condition or underlying abnormality that could compromise the safety of the&#xD;
             subject.&#xD;
&#xD;
        Post-menarchial girls with a positive pregnancy test at randomization, or subjects found&#xD;
        during the screening phase to have hypercalcemia (serum calcium &gt;10.8 mg/dL) or significant&#xD;
        fasting hyperglycemia (fasting blood glucose ≥ 125 mg/dL) will also be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumaravel Rajakumar, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Primary Care Center, Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rajakumar K, Moore CG, Khalid AT, Vallejo AN, Virji MA, Holick MF, Greenspan SL, Arslanian S, Reis SE. Effect of vitamin D3 supplementation on vascular and metabolic health of vitamin D-deficient overweight and obese children: a randomized clinical trial. Am J Clin Nutr. 2020 Apr 1;111(4):757-768. doi: 10.1093/ajcn/nqz340.</citation>
    <PMID>31950134</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>May 18, 2020</results_first_submitted>
  <results_first_submitted_qc>June 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2020</results_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kumaravel Rajakumar</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>Vascular Function</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT01797302/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3 2000 IU</title>
          <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D3 1000 IU</title>
          <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="P3">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Visit</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3 2000 IU</title>
          <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D3 1000 IU</title>
          <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="B3">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="76"/>
            <count group_id="B4" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.4"/>
                    <measurement group_id="B2" value="13.5" spread="2.2"/>
                    <measurement group_id="B3" value="13.5" spread="2.3"/>
                    <measurement group_id="B4" value="13.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>&quot;kg/m^2&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="5.8"/>
                    <measurement group_id="B2" value="30.0" spread="6.1"/>
                    <measurement group_id="B3" value="30.7" spread="6.9"/>
                    <measurement group_id="B4" value="30.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obese (BMI &gt; or = 95th percentile)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 25-hydroxyvitamin D (25[OH]D)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="3.5"/>
                    <measurement group_id="B2" value="14.4" spread="3.4"/>
                    <measurement group_id="B3" value="14.3" spread="4.3"/>
                    <measurement group_id="B4" value="14.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum parathyroid hormone (PTH)</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="19.9"/>
                    <measurement group_id="B2" value="45.7" spread="18.0"/>
                    <measurement group_id="B3" value="51.7" spread="20.6"/>
                    <measurement group_id="B4" value="49.8" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow-mediated Dilation (FMD) Percentage</title>
        <description>Brachial artery flow-mediated dilation percentage is a measure of endothelial function. FMD percentage calculation is based on baseline brachial artery diameter(brachialADbase) and change in brachial artery diameter (brachialADchange) during post-occlusive reactive hyperemia. FMD% was determined using the formula (brachialADchange/brachialADbase) x 100.</description>
        <time_frame>6 months</time_frame>
        <population>Intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Dilation (FMD) Percentage</title>
          <description>Brachial artery flow-mediated dilation percentage is a measure of endothelial function. FMD percentage calculation is based on baseline brachial artery diameter(brachialADbase) and change in brachial artery diameter (brachialADchange) during post-occlusive reactive hyperemia. FMD% was determined using the formula (brachialADchange/brachialADbase) x 100.</description>
          <population>Intention to treat with all available data</population>
          <units>percentage of baseline dilation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="5.15"/>
                    <measurement group_id="O2" value="8.27" spread="5.92"/>
                    <measurement group_id="O3" value="7.31" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>interaction term from model group*time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse-wave Velocity (PWV)</title>
        <description>PWV is a measure of arterial stiffness. Higher values of PWV indicate greater degree of arterial stiffness.</description>
        <time_frame>6 months</time_frame>
        <population>intention to tread with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse-wave Velocity (PWV)</title>
          <description>PWV is a measure of arterial stiffness. Higher values of PWV indicate greater degree of arterial stiffness.</description>
          <population>intention to tread with all available data</population>
          <units>meters/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="0.76"/>
                    <measurement group_id="O2" value="4.85" spread="0.63"/>
                    <measurement group_id="O3" value="4.88" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>interaction term for group*time</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Augmentation Index at Heart Rate of 75 Beats/Min (AIx-75)</title>
        <description>AIx-75 is a measure of arterial stiffness. AIx was measured through radial arterial tonometry using SphygmoCor.&#xD;
Radial pulse waveform are analyzed through an automatic software function to determine aortic pulse waveform and aortic or central systolic (cSBP) and diastolic blood pressure (cDBP), and these measurements are further analyzed automatically to calculate AIx.&#xD;
AIx is a composite measure of the magnitude of wave reflection and arterial stiffness in all conduit arteries which affect the timing of the wave reflection. AIx = P2-P1/cSBP-cDBP, where P1 is the height of the incident pressure wave form during systole, P2 is the height of the reflected wave added to the incident wave, cSBP is the aortic systolic BP, and cDBP is the aortic diastolic BP. AIx adjusted to heart rate of 75 beats/min (AIx-75) is a validated index of arterial stiffness, with higher values indicating higher degree of arterial stiffness.</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Augmentation Index at Heart Rate of 75 Beats/Min (AIx-75)</title>
          <description>AIx-75 is a measure of arterial stiffness. AIx was measured through radial arterial tonometry using SphygmoCor.&#xD;
Radial pulse waveform are analyzed through an automatic software function to determine aortic pulse waveform and aortic or central systolic (cSBP) and diastolic blood pressure (cDBP), and these measurements are further analyzed automatically to calculate AIx.&#xD;
AIx is a composite measure of the magnitude of wave reflection and arterial stiffness in all conduit arteries which affect the timing of the wave reflection. AIx = P2-P1/cSBP-cDBP, where P1 is the height of the incident pressure wave form during systole, P2 is the height of the reflected wave added to the incident wave, cSBP is the aortic systolic BP, and cDBP is the aortic diastolic BP. AIx adjusted to heart rate of 75 beats/min (AIx-75) is a validated index of arterial stiffness, with higher values indicating higher degree of arterial stiffness.</description>
          <population>intention to treat with all available data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="8.44"/>
                    <measurement group_id="O2" value="2.22" spread="10.97"/>
                    <measurement group_id="O3" value="1.74" spread="10.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Systolic Blood Pressure</title>
        <description>a measure of cardiometabolic health</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Central Systolic Blood Pressure</title>
          <description>a measure of cardiometabolic health</description>
          <population>intention to treat with all available data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.45" spread="7.20"/>
                    <measurement group_id="O2" value="96.05" spread="8.19"/>
                    <measurement group_id="O3" value="98.50" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Diastolic Blood Pressure</title>
        <description>a measure of cardiometabolic health</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Central Diastolic Blood Pressure</title>
          <description>a measure of cardiometabolic health</description>
          <population>intention to treat with all available data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.69" spread="5.87"/>
                    <measurement group_id="O2" value="65.33" spread="8.27"/>
                    <measurement group_id="O3" value="68.57" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0117</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Systolic Blood Pressure</title>
        <description>a measure of cardiometabolic health</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Systolic Blood Pressure</title>
          <description>a measure of cardiometabolic health</description>
          <population>intention to treat with all available data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.71" spread="8.45"/>
                    <measurement group_id="O2" value="114.88" spread="11.76"/>
                    <measurement group_id="O3" value="115.70" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Diastolic Blood Pressure</title>
        <description>a measure of cardiometabolic health</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Diastolic Blood Pressure</title>
          <description>a measure of cardiometabolic health</description>
          <population>intention to treat with all available data</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.57" spread="5.81"/>
                    <measurement group_id="O2" value="64.73" spread="8.44"/>
                    <measurement group_id="O3" value="67.30" spread="6.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0256</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose</title>
        <description>a measure of cardiometabolic health</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose</title>
          <description>a measure of cardiometabolic health</description>
          <population>intention to treat with all available data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.41" spread="6.33"/>
                    <measurement group_id="O2" value="88.48" spread="7.05"/>
                    <measurement group_id="O3" value="90.44" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0945</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1/Fasting Insulin Ratio</title>
        <description>1/fasting insulin ratio is a measure of insulin sensitivity. Increases in 1/fasting insulin ratio indicate improvements in insulin sensitivity.</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>1/Fasting Insulin Ratio</title>
          <description>1/fasting insulin ratio is a measure of insulin sensitivity. Increases in 1/fasting insulin ratio indicate improvements in insulin sensitivity.</description>
          <population>intention to treat with all available data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.06"/>
                    <measurement group_id="O2" value="0.06" spread="0.04"/>
                    <measurement group_id="O3" value="0.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Body Mass Index (BMI)</title>
        <description>a surrogate measure of adiposity</description>
        <time_frame>6 months</time_frame>
        <population>intention to treat with all available data</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3 2000 IU</title>
            <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D3 1000 IU</title>
            <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D3 600 IU</title>
            <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>a surrogate measure of adiposity</description>
          <population>intention to treat with all available data</population>
          <units>&quot;kg/m^2&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.82" spread="6.12"/>
                    <measurement group_id="O2" value="30.99" spread="6.41"/>
                    <measurement group_id="O3" value="30.62" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0094</p_value>
            <p_value_desc>interaction term group*time from linear mixed model</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3 2000 IU</title>
          <description>Vitamin D3 2000 IU tablet once daily by mouth for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D3 1000 IU</title>
          <description>Vitamin D3 1000 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
        <group group_id="E3">
          <title>Vitamin D3 600 IU</title>
          <description>Vitamin D3 600 IU tablet by mouth once daily for 6 months&#xD;
Vitamin D3: Tablet form</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning, and proc complications other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous disorders other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our findings of reductions in central-systolic BP and fasting glucose concentrations and improvement in insulin sensitivity lack adjustment for multiplicity and therefore should be considered as hypothesis-generating and interpreted with caution.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kumaravel Rajakumar</name_or_title>
      <organization>University of Pittsburgh School of Medicine</organization>
      <phone>412-692-5822</phone>
      <email>kumaravel.rajakumar@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

